J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perloff, M.
Right arrow Articles by Greenblatt, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perloff, M.
Right arrow Articles by Greenblatt, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir

MD Perloff, LL von Moltke, and DJ Greenblatt

This study investigated fexofenadine (FXD) transport and the inhibition of FXD transport in Caco-2 cell monolayer transwells, using rhodamine 123 (RH123) transport as a positive control. FXD transport from the basolateral (B) to apical (A) compartment was fivefold higher than A to B transport. FXD transport was linear with respect to time (up to 270 min) and concentration (up to 300 microm). Similar results were seen with the positive control RH123. Ritonavir (100 PM) and verapamil (100 microm) reduced transport of FXD and RH123 by more than 80%, whereas transport was not inhibited by 100 m indomethacin or 2 mM probenecid. This suggests predominantly P-glycoprotein (P-gp)-mediated transport as opposed to transport by multidrug resistance protein. In concentration-response experiments, FXD transport was inhibited by verapamil and ritonavir with IC50 values of 6.5 microm and 5.4 microm, respectively. Results from this in vitro study demonstrate differential transport of FXD across Caco-2 cell monolayers and inhibition of FXD transport by established P-gp inhibitors. Thefindings support the use of FXD as an index or probe compound to reflect P-gp activity in vivo.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
K. Ohura, H. Sakamoto, S.-i. Ninomiya, and T. Imai
Development of a Novel System for Estimating Human Intestinal Absorption Using Caco-2 Cells in the Absence of Esterase Activity
Drug Metab. Dispos., February 1, 2010; 38(2): 323 - 331.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. Liu, P. M. Beringer, L. Hidayat, A. P. Rao, S. Louie, G. J. Burckart, and B. Shapiro
Probenecid, but Not Cystic Fibrosis, Alters the Total and Renal Clearance of Fexofenadine
J. Clin. Pharmacol., August 1, 2008; 48(8): 957 - 965.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Uno, M. Shimizu, K. Sugawara, and T. Tateishi
Lack of Dose-Dependent Effects of Itraconazole on the Pharmacokinetic Interaction with Fexofenadine
Drug Metab. Dispos., November 1, 2006; 34(11): 1875 - 1879.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Petri, E. Bergman, P. Forsell, M. Hedeland, U. Bondesson, L. Knutson, and H. Lennernas
FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL
Drug Metab. Dispos., July 1, 2006; 34(7): 1182 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. P. G. van Heeswijk, M. Bourbeau, P. Campbell, I. Seguin, B. M. Chauhan, B. C. Foster, and D. W. Cameron
Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
J. Clin. Pharmacol., July 1, 2006; 46(7): 758 - 767.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Tahara, H. Kusuhara, E. Fuse, and Y. Sugiyama
P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETION
Drug Metab. Dispos., July 1, 2005; 33(7): 963 - 968.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. S. Perloff, S. X. Duan, P. R. Skolnik, D. J. Greenblatt, and L. L. von Moltke
ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO
Drug Metab. Dispos., June 1, 2005; 33(6): 764 - 770.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
E. D. Kharasch, A. Walker, C. Hoffer, and P. Sheffels
Evaluation of First-Pass Cytochrome P4503A (CYP3A) and P-Glycoprotein Activities Using Alfentanil and Fexofenadine in Combination
J. Clin. Pharmacol., January 1, 2005; 45(1): 79 - 88.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S.-M. Huang and L. J. Lesko
Drug-Drug, Drug-Dietary Supplement, and Drug-Citrus Fruit and Other Food Interactions: What Have We Learned?
J. Clin. Pharmacol., June 1, 2004; 44(6): 559 - 569.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
E. D. Kharasch, C. Hoffer, T. G. Altuntas, and D. Whittington
Quinidine as a Probe for the Role of P-Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl
J. Clin. Pharmacol., March 1, 2004; 44(3): 224 - 233.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. M. Fogelman, G. Chen, J. A. Graf, P. Mertzanis, S. Byron, K. E. Culm, B. W. Granda, et al.
Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone
J. Clin. Pharmacol., April 1, 2003; 43(4): 414 - 422.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Clinical Pharmacology